Apogee Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Apogee Therapeutics, Inc. (APGE) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $1.70 million for the 11-month period ending 2022-12-31, per its 10-K filed 2024-03-05.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2024-03-05
- 2022-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 11 month $1.70M.
- 2022-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 8 month $1.70M.
- 2022-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 5 month $1.70M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 5 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 8 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 11 month |
|---|---|---|---|
| 2022-12-31 | $1.70M 10-K · filed 2024-03-05 | ||
| 2022-09-30 | $1.70M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $1.70M 10-Q · filed 2023-08-28 |